Kamat Pradip K, Kalani Anuradha, Debnath Nabendu, Mushtaq Zayd, Tyagi Suresh C, Tyagi Neetu
Departments of Neurology, Medical College of Georgia, Augusta University, Augusta, GA, 30912, USA.
Disease Biology Lab and Molecular Oncology Lab, Department of Life Science and Biotechnology, Chhatrapati Shahu Ji Maharaj University, Kanpur, 208024, India.
Geroscience. 2025 May 9. doi: 10.1007/s11357-025-01662-1.
Okadaic acid (OKA) is a marine biotoxin that accumulates in shellfish and is responsible for causing diarrheic shellfish poisoning. OKA is a powerful and selective inhibitor of serine/threonine phosphatases 1 and 2A, which induces hyperphosphorylation of tau in vitro and in vivo leading to Alzheimer's disease (AD)-like pathology and memory impairment. Hydrogen sulfide (HS), a gaseous signaling molecule produced endogenously in the brain, has been demonstrated to possess neuroprotective properties in various models of neurodegeneration. The aim of this study was to investigate the potential of H₂S in reducing OKA-induced Alzheimer's disease (AD)-like pathology, focusing on its effects on the GSK3β/Tau and CaMKII/CREB signaling pathways in mice. To test this hypothesis, we used age 8-10 weeks-old male C57BL/6J wild-type mice, divided into the following experimental groups: 1. Control group: Received a single intracerebroventricular (ICV) injection of artificial cerebrospinal fluid (aCSF). 2. WT + OKA group: Received a single ICV injection of OKA (100 ng/5 µl) bilaterally to induce AD-like pathology. OKA was dissolved in artificial cerebrospinal fluid. 3. WT + OKA + GYY4137 group: Received a single ICV injection of OKA (100 ng/5 µl) bilaterally, followed by GYY4137 (30 µM/kg) via drinking water for 21 days. 4. WT + GYY4137 group: Received only GYY4137 per se (30 µM/kg) via drinking water for 21 days. After the treatment period, synaptic proteins and neurodegeneration were evaluated using Western blotting, RT-PCR, and immunohistochemistry techniques. Our results demonstrate that OKA administration results in memory impairment with decreased cerebral blood flow (CBF). OKA also caused a significant decrease in synapse proteins (PSD95, MAP-2, BDNF, CaMKIIα, and Tubulin-3β) levels, along with increased expression of Tau, PHF-1, and GSK-3β and memory-associated signaling molecules and pCREB. Interestingly, IP administration of GYY4137 (30 µM/Kg; an HS donor) for 21 days significantly improved the level of synapse proteins and memory function in OKA-treated mice. The findings of this study determine the neuroprotective mechanism of HS in OKA-induced AD-like pathology through the modulation of Tau, GSK3β, and pCREB signaling. Therefore, HS ameliorates OKA-induced memory impairment by improving synapse function and forgetfulness. As a result, HS could be used as a promising therapeutic molecule against Alzheimer's disease-like pathology.
冈田酸(OKA)是一种在贝类中蓄积的海洋生物毒素,可导致腹泻性贝类中毒。OKA是丝氨酸/苏氨酸磷酸酶1和2A的强效选择性抑制剂,在体外和体内均可诱导tau蛋白过度磷酸化,导致类似阿尔茨海默病(AD)的病理变化和记忆障碍。硫化氢(HS)是大脑中内源性产生的一种气体信号分子,已被证明在各种神经退行性疾病模型中具有神经保护特性。本研究的目的是探讨H₂S在减轻OKA诱导的类似阿尔茨海默病(AD)病理变化方面的潜力,重点关注其对小鼠GSK3β/Tau和CaMKII/CREB信号通路的影响。为了验证这一假设,我们使用了8-10周龄的雄性C57BL/6J野生型小鼠,分为以下实验组:1. 对照组:接受单次脑室内(ICV)注射人工脑脊液(aCSF)。2. WT+OKA组:双侧接受单次ICV注射OKA(100 ng/5 μl)以诱导类似AD的病理变化。OKA溶解于人工脑脊液中。3. WT+OKA+GYY4137组:双侧接受单次ICV注射OKA(100 ng/5 μl),随后通过饮用水给予GYY4137(30 μM/kg),持续21天。4. WT+GYY4137组:仅通过饮用水给予GYY4137本身(30 μM/kg),持续21天。治疗期结束后,使用蛋白质免疫印迹法、逆转录-聚合酶链反应和免疫组织化学技术评估突触蛋白和神经退行性变情况。我们的结果表明,给予OKA会导致记忆障碍并伴有脑血流量(CBF)降低。OKA还导致突触蛋白(PSD95、MAP-2、脑源性神经营养因子、CaMKIIα和微管蛋白-3β)水平显著降低,同时Tau、PHF-1、GSK-3β以及与记忆相关的信号分子和pCREB的表达增加。有趣的是,腹腔注射GYY4137(30 μM/Kg;一种HS供体)21天可显著改善OKA处理小鼠的突触蛋白水平和记忆功能。本研究结果确定了HS通过调节Tau、GSK3β和pCREB信号通路在OKA诱导的类似AD病理变化中的神经保护机制。因此,HS通过改善突触功能和健忘症状减轻了OKA诱导的记忆障碍。结果表明,HS可作为一种有前景的治疗分子用于对抗类似阿尔茨海默病的病理变化。